Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 2
2015 3
2016 2
2017 3
2019 1
2020 3
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF. Ma C, et al. Among authors: eggert t. Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2. Nature. 2016. PMID: 26934227 Free PMC article.
Hepatic myeloid-derived suppressor cells in cancer.
Medina-Echeverz J, Eggert T, Han M, Greten TF. Medina-Echeverz J, et al. Among authors: eggert t. Cancer Immunol Immunother. 2015 Aug;64(8):931-40. doi: 10.1007/s00262-015-1736-y. Epub 2015 Jul 2. Cancer Immunol Immunother. 2015. PMID: 26133122 Free PMC article. Review.
Tumor regulation of the tissue environment in the liver.
Eggert T, Greten TF. Eggert T, et al. Pharmacol Ther. 2017 May;173:47-57. doi: 10.1016/j.pharmthera.2017.02.005. Epub 2017 Feb 4. Pharmacol Ther. 2017. PMID: 28167218 Free PMC article. Review.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, McComb M, Wittemer-Rump S, Koca G, Stienen S, Bargou RC, Hummel HD, Loidl W, Grüllich C, Eggert T, Tran B, Mytych DT. Penny HL, et al. Among authors: eggert t. Front Immunol. 2023 Oct 23;14:1261070. doi: 10.3389/fimmu.2023.1261070. eCollection 2023. Front Immunol. 2023. PMID: 37942314 Free PMC article.
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Dorff T, et al. Among authors: eggert t. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. Clin Cancer Res. 2024. PMID: 38300720 Clinical Trial.
18 results